PURPOSE: Tumor mutational profiling is increasingly performed in patients with advanced cancer. We determined the extent to which germline mutation profiling guides therapy selection in patients with advanced cancer. METHODS: Patients with cancer undergoing tumor genomic profiling were prospectively consented for germline cancer predisposition gene analysis (2015-2019). In patients harboring germline likely pathogenic or pathogenic (LP/P) alterations, therapeutic actionability was classified using a precision oncology knowledge base. Patients with metastatic or recurrent cancer receiving germline genotype-directed therapy were determined. RESULTS: Among 11,947 patients across > 50 malignancies, 17% (n = 2,037) harbored a germline LP/P variant. By oncology knowledge base classification, 9% (n = 1042) had an LP/P variant in a gene with therapeutic implications (4% level 1; 4% level 3B; < 1% level 4). BRCA1/2 variants accounted for 42% of therapeutically actionable findings, followed by CHEK2 (13%), ATM (12%), mismatch repair genes (11%), and PALB2 (5%). When limited to the 9,079 patients with metastatic or recurrent cancer, 8% (n = 710) harbored level 1 or 3B genetic findings and 3.2% (n = 289) received germline genotype-directed therapy. Germline genotype-directed therapy was received by 61% and 18% of metastatic cancer patients with level 1 and level 3B findings, respectively, and by 54% of BRCA1/2, 75% of mismatch repair, 43% of PALB2, 35% of RAD51C/D, 24% of BRIP1, and 19% of ATM carriers. Of BRCA1/2 patients receiving a poly(ADP-ribose) polymerase inhibitor, 45% (84 of 188) had tumors other than breast or ovarian cancer, wherein the drug, at time of delivery, was delivered in an investigational setting. CONCLUSION: In a pan-cancer analysis, 8% of patients with advanced cancer harbored a germline variant with therapeutic actionability with 40% of these patients receiving germline genotype-directed treatment. Germline sequence analysis is additive to tumor sequence analysis for therapy selection and should be considered for all patients with advanced cancer.
PURPOSE: Tumor mutational profiling is increasingly performed in patients with advanced cancer. We determined the extent to which germline mutation profiling guides therapy selection in patients with advanced cancer. METHODS: Patients with cancer undergoing tumor genomic profiling were prospectively consented for germline cancer predisposition gene analysis (2015-2019). In patients harboring germline likely pathogenic or pathogenic (LP/P) alterations, therapeutic actionability was classified using a precision oncology knowledge base. Patients with metastatic or recurrent cancer receiving germline genotype-directed therapy were determined. RESULTS: Among 11,947 patients across > 50 malignancies, 17% (n = 2,037) harbored a germline LP/P variant. By oncology knowledge base classification, 9% (n = 1042) had an LP/P variant in a gene with therapeutic implications (4% level 1; 4% level 3B; < 1% level 4). BRCA1/2 variants accounted for 42% of therapeutically actionable findings, followed by CHEK2 (13%), ATM (12%), mismatch repair genes (11%), and PALB2 (5%). When limited to the 9,079 patients with metastatic or recurrent cancer, 8% (n = 710) harbored level 1 or 3B genetic findings and 3.2% (n = 289) received germline genotype-directed therapy. Germline genotype-directed therapy was received by 61% and 18% of metastatic cancer patients with level 1 and level 3B findings, respectively, and by 54% of BRCA1/2, 75% of mismatch repair, 43% of PALB2, 35% of RAD51C/D, 24% of BRIP1, and 19% of ATM carriers. Of BRCA1/2 patients receiving a poly(ADP-ribose) polymerase inhibitor, 45% (84 of 188) had tumors other than breast or ovarian cancer, wherein the drug, at time of delivery, was delivered in an investigational setting. CONCLUSION: In a pan-cancer analysis, 8% of patients with advanced cancer harbored a germline variant with therapeutic actionability with 40% of these patients receiving germline genotype-directed treatment. Germline sequence analysis is additive to tumor sequence analysis for therapy selection and should be considered for all patients with advanced cancer.
Authors: Mary B Daly; Robert Pilarski; Matthew B Yurgelun; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Judy E Garber; Michael Goggins; Mollie L Hutton; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Tuya Pal; Holly J Pederson; Gwen Reiser; Kristen Mahoney Shannon; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Mary A Dwyer; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2020-04 Impact factor: 11.908
Authors: Dong-Wan Kim; Marcello Tiseo; Myung-Ju Ahn; Karen L Reckamp; Karin Holmskov Hansen; Sang-We Kim; Rudolf M Huber; Howard L West; Harry J M Groen; Maximilian J Hochmair; Natasha B Leighl; Scott N Gettinger; Corey J Langer; Luis G Paz-Ares Rodríguez; Egbert F Smit; Edward S Kim; William Reichmann; Frank G Haluska; David Kerstein; D Ross Camidge Journal: J Clin Oncol Date: 2017-05-05 Impact factor: 44.544
Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245
Authors: Jean Y Tang; Julian M Mackay-Wiggan; Michelle Aszterbaum; Robert L Yauch; Joselyn Lindgren; Kris Chang; Carol Coppola; Anita M Chanana; Jackleen Marji; David R Bickers; Ervin H Epstein Journal: N Engl J Med Date: 2012-06-07 Impact factor: 91.245
Authors: Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245
Authors: Andrea M Gross; Pamela L Wolters; Eva Dombi; Andrea Baldwin; Patricia Whitcomb; Michael J Fisher; Brian Weiss; AeRang Kim; Miriam Bornhorst; Amish C Shah; Staci Martin; Marie C Roderick; Dominique C Pichard; Amanda Carbonell; Scott M Paul; Janet Therrien; Oxana Kapustina; Kara Heisey; D Wade Clapp; Chi Zhang; Cody J Peer; William D Figg; Malcolm Smith; John Glod; Jaishri O Blakeley; Seth M Steinberg; David J Venzon; L Austin Doyle; Brigitte C Widemann Journal: N Engl J Med Date: 2020-03-18 Impact factor: 91.245
Authors: Mark A Dickson; William D Tap; Mary Louise Keohan; Sandra P D'Angelo; Mrinal M Gounder; Cristina R Antonescu; Jonathan Landa; Li-Xuan Qin; Dustin D Rathbone; Mercedes M Condy; Yelena Ustoyev; Aimee M Crago; Samuel Singer; Gary K Schwartz Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544
Authors: Linda Huang; Helen Fernandes; Hamid Zia; Peyman Tavassoli; Hanna Rennert; David Pisapia; Marcin Imielinski; Andrea Sboner; Mark A Rubin; Michael Kluk; Olivier Elemento Journal: J Am Med Inform Assoc Date: 2017-05-01 Impact factor: 4.497
Authors: Paolo Grassi; Elena Verzoni; Raffaele Ratta; Alessia Mennitto; Filippo de Braud; Giuseppe Procopio Journal: Drug Des Devel Ther Date: 2016-07-05 Impact factor: 4.162
Authors: Natalie M Reizine; Keith Danahey; Tien M Truong; David George; Larry K House; Theodore G Karrison; Xander M R van Wijk; Kiang-Teck J Yeo; Mark J Ratain; Peter H O'Donnell Journal: Cancer Date: 2022-01-28 Impact factor: 6.921
Authors: Shuai Li; Valentina Silvestri; Goska Leslie; Timothy R Rebbeck; Susan L Neuhausen; John L Hopper; Henriette Roed Nielsen; Andrew Lee; Xin Yang; Lesley McGuffog; Michael T Parsons; Irene L Andrulis; Norbert Arnold; Muriel Belotti; Åke Borg; Bruno Buecher; Saundra S Buys; Sandrine M Caputo; Wendy K Chung; Chrystelle Colas; Sarah V Colonna; Jackie Cook; Mary B Daly; Miguel de la Hoya; Antoine de Pauw; Hélène Delhomelle; Jacqueline Eason; Christoph Engel; D Gareth Evans; Ulrike Faust; Tanja N Fehm; Florentia Fostira; George Fountzilas; Megan Frone; Vanesa Garcia-Barberan; Pilar Garre; Marion Gauthier-Villars; Andrea Gehrig; Gord Glendon; David E Goldgar; Lisa Golmard; Mark H Greene; Eric Hahnen; Ute Hamann; Helen Hanson; Tiara Hassan; Julia Hentschel; Judit Horvath; Louise Izatt; Ramunas Janavicius; Yue Jiao; Esther M John; Beth Y Karlan; Sung-Won Kim; Irene Konstantopoulou; Ava Kwong; Anthony Laugé; Jong Won Lee; Fabienne Lesueur; Noura Mebirouk; Alfons Meindl; Emmanuelle Mouret-Fourme; Hannah Musgrave; Joanne Ngeow Yuen Yie; Dieter Niederacher; Sue K Park; Inge Sokilde Pedersen; Juliane Ramser; Susan J Ramus; Johanna Rantala; Muhammad U Rashid; Florian Reichl; Julia Ritter; Andreas Rump; Marta Santamariña; Claire Saule; Gunnar Schmidt; Rita K Schmutzler; Leigha Senter; Saba Shariff; Christian F Singer; Melissa C Southey; Dominique Stoppa-Lyonnet; Christian Sutter; Yen Tan; Soo Hwang Teo; Mary Beth Terry; Mads Thomassen; Marc Tischkowitz; Amanda E Toland; Diana Torres; Ana Vega; Sebastian A Wagner; Shan Wang-Gohrke; Barbara Wappenschmidt; Bernhard H F Weber; Drakoulis Yannoukakos; Amanda B Spurdle; Douglas F Easton; Georgia Chenevix-Trench; Laura Ottini; Antonis C Antoniou Journal: J Clin Oncol Date: 2022-01-25 Impact factor: 50.717
Authors: Jada G Hamilton; Smita C Banerjee; Sigrid V Carlsson; Jacqueline Vera; Kathleen A Lynch; Lili Sar-Graycar; Chloé M Martin; Patricia A Parker; Jennifer L Hay Journal: Per Med Date: 2021-10-22 Impact factor: 2.119
Authors: Brittany L Bychkovsky; Tianyu Li; Jilliane Sotelo; Nabihah Tayob; Joanna Mercado; Israel Gomy; Anu Chittenden; Sarah Kane; Samantha Stokes; Melissa E Hughes; Ji Seok Kim; Renato Umeton; Mark M Awad; Panagiotis A Konstantinopoulos; Matthew B Yurgelun; Brian M Wolpin; Mary-Ellen Taplin; Randall E Newmark; Bruce E Johnson; Neal I Lindeman; Laura E MacConaill; Judy E Garber; Nancy U Lin Journal: Clin Cancer Res Date: 2022-06-01 Impact factor: 13.801
Authors: Semanti Mukherjee; Chaitanya Bandlamudi; Matthew D Hellmann; Yelena Kemel; Esther Drill; Hira Rizvi; Kaitlyn Tkachuk; Aliya Khurram; Michael F Walsh; Marjorie G Zauderer; Diana Mandelker; Sabine Topka; Ahmet Zehir; Preethi Srinivasan; Myvizhi Esai Selvan; Maria I Carlo; Karen A Cadoo; Alicia Latham; Jada G Hamilton; Ying L Liu; Steven M Lipkin; Sami Belhadj; Gareth L Bond; Zeynep H Gümüş; Robert J Klein; Marc Ladanyi; David B Solit; Mark E Robson; David R Jones; Mark G Kris; Joseph Vijai; Zsofia K Stadler; Christopher I Amos; Barry S Taylor; Michael F Berger; Charles M Rudin; Kenneth Offit Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-07-01 Impact factor: 4.090